Prandin
This product is formulated for type 2 diabetes mellitus intended to mitigate glucose swings and support long-term metabolic control.
Strengths: 0.5 · 1 · 2mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
NovoNorm
- Therapeutic class
Meglitinide Antidiabetic
- Pharmacological class
Meglitinide
- Contraindications
hypersensitivity to repaglinide; type 1 diabetes mellitus; diabetic ketoacidosis
- Precautions and warnings
monitor for hypoglycaemia; take immediately before meals
- Minor side effects
hypoglycaemia; abdominal pain
- Moderate side effects
nausea; diarrhoea
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Novo Nordisk
- Onset Time
15–30 minutes
- Duration
4–6 hours
- Storage instructions
Store below 25°C in the original container.
- Drug interactions
Gemfibrozil; Alcohol
- Age restrictions
Not recommended under 18 years.
- Pregnancy and breastfeeding
Pregnancy: Should not be used. Breastfeeding: Not recommended.
Serious side effects
severe hypoglycaemia — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
This product is formulated for type 2 diabetes mellitus intended to mitigate glucose swings and support long-term metabolic control.
Mechanism of action
Repaglinide stimulates insulin release from the pancreas by closing ATP-dependent potassium channels in the membrane of pancreatic beta cells, which depolarizes the cell and opens calcium channels.
Prandin
This product is formulated for type 2 diabetes mellitus intended to mitigate glucose swings and support long-term metabolic control.
Editorial Notes
- Active ingredient(s): Repaglinide
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 180 tablets - 0.5 mg442-0-5-mg-3861
- 90 tablets - 1 mg442-1-mg-3865
- 60 tablets - 2 mg442-2-mg-3870